journal article·2018-12-10

Supercritical Fluid-Assisted Decoration of Nanoparticles on Porous Microcontainers for Codelivery of Therapeutics and Inhalation Therapy of Diabetes

Ranjith Kumar Kankala, Xiao-Fen Lin, Hu-Fan Song, Shi-Bin Wang, Da-Yun Yang, Yu Shrike Zhang, Ai-Zheng Chen

Publisher page

Abstract

The impact of nanotechnology and its advancements have allowed us to explore new therapeutic modalities. To this end, we designed nanoparticles-inlaid porous microparticles (NIPMs) coloaded with small interfering RNA (siRNA) and glucagon-like peptide-1 (GLP-1) using the supercritical carbon dioxide (SC–CO2) technology as an inhalation delivery system for diabetes therapy. siRNA-encapsulating chitosan (CS) nanoparticles were first synthesized by an ionic gelation method, which resulted in particles with small sizes (100–150 nm), high encapsulation efficiency (∼94.8%), and sustained release performance (∼60% in 32 h). These CS nanoparticles were then loaded with GLP-1-dispersed poly-l-lactide (PLLA) porous microparticles (PMs) by SC–CO2-assisted precipitation with the compressed antisolvent (PCA) process. The hypoglycemic efficacy of NIPMs administered via pulmonary route in mice persisted longer due to sustained release of siRNA from CS nanoparticles and the synergistic effects of GLP-1 in PMs, which significantly inhibited the expression of dipeptidyl peptidase-4 mRNA (DPP-4-mRNA). This ecofriendly technology provides a convenient way to fabricate nanoparticle-microparticle composites for codelivery of a gene and a therapeutic peptide, which will potentially find widespread applications in the field of pharmaceutics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advanced Drug Delivery Systems · Microencapsulation and Drying Processes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen 361021, P. R. China

Fujian Provincial Key Laboratory of Biochemical Technology, Huaqiao University, Xiamen 361021, P. R. China

Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China

Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States

Funding

Huaqiao University · National Natural Science Foundation of China · Public Science and Technology Research Funds Projects of Ocean · Fujian Province

References (65)

Show source-provided references
1. 10.1093/ageing/afw14010.1093/ageing/afw140 ↗
2. 10.3390/nano705011210.3390/nano7050112 ↗
3. 10.1080/10717544.2017.138120010.1080/10717544.2017.1381200 ↗
4. 10.1021/bm500364a10.1021/bm500364a ↗
5. 10.2337/dc09-903210.2337/dc09-9032 ↗
6. 10.1208/s12249-018-1081-510.1208/s12249-018-1081-5 ↗
7. 10.1002/adhm.20180091010.1002/adhm.201800910 ↗
8. 10.1192/bjp.122.3.33710.1192/bjp.122.3.337 ↗
9. 10.2165/00002018-200427120-0000210.2165/00002018-200427120-00002 ↗
10. Chen C. · Am. J. Health Syst. Pharm. · 1998 · 55 · 90510.1093/ajhp/55.9.905 ↗
11. 10.1016/j.biomaterials.2010.10.04510.1016/j.biomaterials.2010.10.045 ↗
12. 10.1210/jcem.87.3.835510.1210/jcem.87.3.8355 ↗
13. 10.1177/106002801456418010.1177/1060028014564180 ↗
14. 10.2337/db14-069410.2337/db14-0694 ↗
15. 10.1016/j.biomaterials.2013.01.01310.1016/j.biomaterials.2013.01.013 ↗
16. 10.1016/S0140-6736(06)69705-510.1016/S0140-6736(06)69705-5 ↗
17. 10.1111/j.1463-1326.2007.00705.x10.1111/j.1463-1326.2007.00705.x ↗
18. 10.1016/j.clinthera.2012.04.01310.1016/j.clinthera.2012.04.013 ↗
19. 10.1016/j.ejps.2011.10.02910.1016/j.ejps.2011.10.029 ↗
20. 10.1097/ICU.0b013e3283541eb610.1097/ICU.0b013e3283541eb6 ↗
21. 10.1208/s12248-010-9210-410.1208/s12248-010-9210-4 ↗
22. 10.1016/j.bbrc.2016.02.01910.1016/j.bbrc.2016.02.019 ↗
23. 10.1016/j.ijpharm.2010.03.01710.1016/j.ijpharm.2010.03.017 ↗
24. 10.1038/nrd215310.1038/nrd2153 ↗
25. 10.1023/A:101442653093510.1023/A:1014426530935 ↗
26. 10.1002/adhm.20170043310.1002/adhm.201700433 ↗
27. 10.1016/j.jconrel.2012.07.00310.1016/j.jconrel.2012.07.003 ↗
28. 10.1016/j.ejps.2006.05.00510.1016/j.ejps.2006.05.005 ↗
29. 10.1016/j.supflu.2015.03.01010.1016/j.supflu.2015.03.010 ↗
30. 10.1126/science.276.5320.186810.1126/science.276.5320.1868 ↗
31. 10.1016/j.biomaterials.2008.12.04410.1016/j.biomaterials.2008.12.044 ↗
32. 10.1016/j.jconrel.2008.12.01110.1016/j.jconrel.2008.12.011 ↗
33. 10.4093/dmj.2011.35.4.31710.4093/dmj.2011.35.4.317 ↗
34. 10.1016/j.biomaterials.2013.05.01810.1016/j.biomaterials.2013.05.018 ↗
35. 10.1016/j.powtec.2014.03.04310.1016/j.powtec.2014.03.043 ↗
36. 10.2147/IJN.S16612410.2147/IJN.S166124 ↗
37. 10.1021/acsbiomaterials.8b0070510.1021/acsbiomaterials.8b00705 ↗
38. 10.1016/j.supflu.2017.11.01610.1016/j.supflu.2017.11.016 ↗
39. 10.1002/wnan.123310.1002/wnan.1233 ↗
40. 10.4028/www.scientific.net/JBBTE.11.9310.4028/www.scientific.net/JBBTE.11.93 ↗
41. Chinese Pharmacopoeia Commission · 2015 · 1
42. 10.1016/j.ymthe.2006.04.01010.1016/j.ymthe.2006.04.010 ↗
43. 10.1155/2013/14632010.1155/2013/146320 ↗
44. 10.1016/j.ijpharm.2013.03.00910.1016/j.ijpharm.2013.03.009 ↗
45. 10.2147/IJN.S16939910.2147/IJN.S169399 ↗
46. 10.1016/j.addr.2014.05.01710.1016/j.addr.2014.05.017 ↗
47. 10.1615/CritRevTherDrugCarrierSyst.201400828510.1615/CritRevTherDrugCarrierSyst.2014008285 ↗
48. 10.1615/CritRevTherDrugCarrierSyst.v19.i45.4010.1615/CritRevTherDrugCarrierSyst.v19.i45.40 ↗
49. 10.1039/c3tb20468e10.1039/c3tb20468e ↗
50. 10.1016/j.supflu.2015.03.01010.1016/j.supflu.2015.03.010 ↗
51. 10.1016/0031-6865(96)00014-310.1016/0031-6865(96)00014-3 ↗
52. 10.1002/adma.20140095310.1002/adma.201400953 ↗
53. 10.1007/s11051-014-2602-010.1007/s11051-014-2602-0 ↗
54. 10.1021/acs.molpharmaceut.7b0053210.1021/acs.molpharmaceut.7b00532 ↗
55. 10.1016/j.colsurfb.2018.08.03710.1016/j.colsurfb.2018.08.037 ↗
56. 10.1021/acsbiomaterials.8b0011610.1021/acsbiomaterials.8b00116 ↗
57. 10.1016/j.ijpharm.2010.05.03210.1016/j.ijpharm.2010.05.032 ↗
58. 10.1080/02652048.2016.120234410.1080/02652048.2016.1202344 ↗
59. 10.1016/j.taap.2016.03.00110.1016/j.taap.2016.03.001 ↗
60. 10.1097/01.ta.0000200075.12489.7410.1097/01.ta.0000200075.12489.74 ↗
61. 10.1159/00019657510.1159/000196575 ↗
62. 10.1006/pupt.2000.023110.1006/pupt.2000.0231 ↗
63. 10.1002/ppul.1016110.1002/ppul.10161 ↗
64. 10.1007/s11095-010-0201-z10.1007/s11095-010-0201-z ↗
65. 10.2174/138161282166615100812432210.2174/1381612821666151008124322 ↗